Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org)

利物浦 COVID-19 药物相互作用 (www.covid19-druginteractions.org)

• 批准号: MR/V020498/1
• 负责人: Saye Khoo
• 金额: $ 8.43万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FV020498%2F1
• 关键词: Liverpool; COVID; 19; Drug; Interactions; Liverpool; COVID; 19; Drug; Interactions

The Liverpool University Drug Interactions group has over twenty years' experience in developing prescribing support resources in infectious diseases, demonstrated by our world-renowned HIV and Hepatitis drug interaction websites (www.hiv-druginteractions.org and www.hep-druginteractions.org) and associated Apps. In 2019, these websites had over 50,000 unique monthly visitors searching for >4.5 million interactions. Our websites are recommended in over 30 international treatment guidelines and many national guidelines. In response to the COVID-19 pandemic and to address the pressing need for prescribing support for studies and clinical situations where experimental COVID-19 therapies are being used, we have developed a static drug interactions website (www.covid19-druginteractions.org) providing information on the likelihood of interactions between the experimental agents and commonly prescribed co-medications. We now have to move to develop a fully interactive and searchable website resource with an associated App. The website will be constantly updated and populated with the latest information on experimental therapies with guidance given to clinicians for managing complex patients.

利物浦大学药物互动小组在开发传染病中的支持资源方面拥有超过20年的经验，这是我们世界知名的HIV和肝炎药物互动网站（www.hiv-druginteractions.org和www.hep-drugugintactions.org）和关联的应用程序所证明的。在2019年，这些网站有超过50,000个独特的每月访问者，寻找> 450万个互动。建议在30多个国际治疗指南和许多国家准则中使用我们的网站。为了应对共同-19的大流行，并解决了使用实验性互联-19疗法的迫切需求，我们已经开发了一个静态药物相互作用网站（www.covid19-druginteractions.org），从而提供了有关互动的信息，以实验性的代理人和普通的互动之间提供信息。现在，我们必须采取行动以使用关联的应用程序开发完全交互式和可搜索的网站资源。该网站将不断更新和填充有关实验疗法的最新信息，并提供给临床医生管理复杂患者的指导。